Allstocks.com's Bulletin Board
  Stocks, Over $0.10
  GMED

Post New Topic  Post A Reply
profile | register | preferences | faq | search

UBBFriend: Email This Page to Someone! next newest topic | next oldest topic
Author Topic:   GMED
1BigTip
Member
posted April 12, 2004 14:16     Click Here to See the Profile for 1BigTip     Edit/Delete Message   Reply w/Quote
GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. After establishing the superiority of a treatment protocol in clinical trials, the Company charges patients a reasonable license fee to use the protocol, which is patented. This summer the Company is conducting a nationwide free clinical trial for West Nile virus encephalitis which will be published before the 2005 West Nile virus season begins. If the Company's protocol continues to be successful, GenoMed will market it beginning next year. GenoMed is currently marketing its protocol for delaying or even preventing complications of high blood pressure and diabetes, which affect 80 million Americans, as well as emphysema, which affects another 3 million people in the U.S., as well as 60 million smokers.
http://www.genomedics.com
David W. Moskowitz, MD, MA, FACP of GenoMed Inc.,
+1-314-977-0115, dwmoskowitz@genomedics.com

IP: Logged

1BigTip
Member
posted April 12, 2004 14:18     Click Here to See the Profile for 1BigTip     Edit/Delete Message   Reply w/Quote
Just wanted to start a new thread. This company has much potential! I own it since .054 just 2 months ago! Its now at .17! New PR came out today.

A 79-year-old male patient from Scioto County, Ohio who was admitted two weeks ago in a coma due to viral encephalitis. His antibody titers are still pending, but his case so far is consistent with West Nile virus encephalitis. Within 24 hours of starting GenoMed's treatment, the patient could move his fingers and toes when asked to do so.

IP: Logged

FurrySound
Member
posted April 12, 2004 22:02     Click Here to See the Profile for FurrySound     Edit/Delete Message   Reply w/Quote
Yes. I've been following them for over a year now. Lots of great progress. There is lots of information available on them for your DD.

IP: Logged

roger7485
Member
posted April 13, 2004 02:04     Click Here to See the Profile for roger7485     Edit/Delete Message   Reply w/Quote
Also look into ADOT for a multi year hold. They own a good deal of GMED and have a stranglehold on a multibillion dollar market. Check it out.

IP: Logged

FurrySound
Member
posted April 13, 2004 09:10     Click Here to See the Profile for FurrySound     Edit/Delete Message   Reply w/Quote
Thanks Roger. Will check them out also.

IP: Logged

1BigTip
Member
posted April 22, 2004 12:18     Click Here to See the Profile for 1BigTip     Edit/Delete Message   Reply w/Quote
Hmmm, A SARS outbreak in China was reported today. Could that be why this stock is moving higher? Anyone hold this?

IP: Logged

1BigTip
Member
posted April 22, 2004 15:48     Click Here to See the Profile for 1BigTip     Edit/Delete Message   Reply w/Quote
GMED 10k is out!

Here are the main points:

As of December 31, 2003, we had 125,691,027 shares outstanding. As of December 31, 2003, we had 48,234,831 options outstanding. As of March 18, 2004, we had 187,716,591 shares outstanding.

This is where the additional shares went to:

On January 8, 2004, we sold 4,703,633 shares of our common stock at $0.0213 per share or an aggregate of $100,000 to Research Capital

On January 9, 2004, we sold 11,121,409 shares of our common stock to Advanced Optics Electronics at $0.027 per share or an aggregate of $300,000.

On January 23, 2004, we issued 1,000,000 shares of our common stock to Peter Brooks in connection with his exercise of options granted to him. The options were exercised at $0.006 per share or an aggregate of $6,000.

On February 5, 2004, we issued 6,679,435 shares of our common stock to Research Capital for debt conversion of $180,657.

On February 5, 2004, we issued 100,000 shares of our common stock to Scott Williams in connection with his exercise of options granted to him. The options were exercised at $0.025 per share or an aggregate of $2,500.

On February 6, 2004, we sold 11,121,411 shares of our common stock to Advanced Optics Electronics at $0.027 per share or an aggregate of $300,000.

On February 9, 2004, we issued 769,231 shares of our common stock to Keith Boyer in connection with his exercise of 769,231 warrants at an exercise price of $0.05 or an aggregate exercise price of $38,461.

On March 8, 2004, in connection with our agreement with Pierpoint Investments, we sold 833,333 shares of our common stock to Robin Carr at $0.045 per share or an aggregate of $37,500.

On March 10, 2004, we sold 11,121,410 shares of our common stock to Advanced Optics Electronics at $0.027 per share or an aggregate of $300,000.

On March 11, 2004, in connection with our agreement with Pierpoint Investments, we sold 411,112 shares of our common stock to N. Shah at $0.045 per share or an aggregate of $18,500.

On March 11, 2004, in connection with our agreement with Pierpoint Investments, we sold 411,112 shares of our common stock to A. Desch at $0.045 per share or an aggregate of $18,500.

On March 11, 2004, in connection with our agreement with Pierpoint Investments, we sold 204,445 shares of our common stock to L. Fitzpatrick at $0.045 per share or an aggregate of $9,200.

On March 12, 2004, we sold 6,012,658 shares of our common stock at $0.0632 per share or an aggregate of $380,000 to Research Capital.

On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 200,000 shares of our common stock to L. Fitzpatrick at $0.045 per share or an aggregate of $9,000.

On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 200,000 shares of our common stock to I. Patel at $0.045 per share or an aggregate of $9,000.

On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 200,000 shares of our common stock to D. Limmer at $0.045 per share or an aggregate of $9,000.

On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 200,000 shares of our common stock to Weighill Builders at $0.045 per share or an aggregate of $9,000.

On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 111,112 shares of our common stock to R. Shah at $0.045 per share or an aggregate of $5,000.

On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 150,000 shares of our common stock to L. Peterman at $0.045 per share or an aggregate of $6,750.

On March 18, 2004, in connection with our agreement with Pierpoint Investments, we sold 150,000 shares of our common stock to M. Paerse at $0.045 per share or an aggregate of $6,750.

On March 18, 2004, we issued 6,058,560 shares of common stock to Research Capital for debt conversion of $153,081.

During 2003 we targeted the discovery of disease genes associated with Type 2 Diabetes and Colon Cancer, but lacked the funding to do so. During 2004, our next phase of operations, we have decided to focus solely on identifying genes for common cancers, since we believe we can already prevent type 2 diabetes itself and its complications. Cancer-causing genes affect a large population base with ample opportunities for disease-gene related products and services. The first samples to be collected will involve such common cancers as lung, prostate, colon, breast and pancreas.

We will accomplish our analysis of individual SNPS, as previously defined under "Our Research and Development Approach", through ultra-high throughput (UHT) machines. Genotyping consists of two phases: screening, wherein a relatively small number of cases and controls are genotyped at a large number of SNPs, and validation, wherein a considerably larger number of cases and controls are genotyped at a small number of SNPs. The Orchid UHT machine we purchased and installed at DNAprint Genomics, for example, will accomplish validation genotyping.

To date we have earned only $6,410 of revenues.

Currently, a patient can subscribe to our Clinical Outcomes Improvement Program(tm) for $67 a month. We have twelve such agreements.

During 2001, we spent $333,264 on our research and development. During 2002 and 2003, we spent no funds on research and development.

We have no part-time employees. We have 1 full-time employee, our President/Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Chairman of the Board/Chief Medical Officer, Dr. David Moskowitz, who is responsible for directing our Board of Directors, overseeing all research and development and marketing issues, and supervising all medically-related activities. Additionally, Dr. David Moskowitz is responsible for our overall administration and operation, including finance, marketing, and personnel.

Agreement with Pierpoint Investments SA
On or about March 2, 2004, we entered into a ten year letter of interest with Pierpoint Investments whereby Pierpoint indicated interest in the purchase of $500,000 and $2,000,000 of shares of our common stock per year at the 30 day average of the bid and ask price, less a 25% discount with warrants exercisable at the 30 day average bid and ask price less a 40% discount. During the first year the interests is to purchase $225,000 of common shares at $0.045 per share and an additional $275,000 of shares at the 30 day average bid and ask price less a 25% discount. By investing $225,000 Pierpoint will be eligible to receive 5,000,000 two years warrants exercisable at the 30 day average bid and ask price less a 50% discount. Should the initial $225,000 be received by us, an affiliate of Pierpoint will be eligible to purchase $250,000 of our shares of common stock at $0.045 per share and receive 5,555,556 two year warrants exercisable at 30 day the average bid and ask price less a 50% discount. By investing $500,000 in the first year, Pierpoint will be eligible for a total of 40,000,000 warrants, including the 5,000,000 discussed above. In accordance with the terms of the letter of interest, through April 5, 2004, we issued an aggregate of 3,071,114 shares of our common stock for cash totaling $138,200.

Agreement with E & E Communication
On February 6, 2004, we entered into an agreement with E & E Communications, a public and investor relations company, in which E & E Communications agreed to: (a) assist in the preparation of our news releases and other public announcements; (b) "pitch" our stories to the media, including national, feature and trade press and develop story lines to make us attractive to the major media and financial community; and (c) prepare targeted materials for eh media and potential investors and assist in communications that emphasize the key strengths and competitive advantages of our management, business plan, and technologies. We agree to pay E & E Communications $2,000 a month in exchange for these services. The agreement can be cancelled by E & E Communications or us upon a thirty day notice.

Partnership Agreement with PhenoMed, Sdn Bhd
On September 5, 2003, we entered into an agreement with PhenoMed, Sdn Bhd, doing business as PhenoMed, a Malaysian corporation. This agreement provides that:
o PhenoMed will have the exclusive rights to offer our genomic medical technologies and disease management therapeutics to all customers in the Asia Pacific region, which broadly encompasses that portion of the globe stretching from Western Samoa in the Pacific to Pakistan in the east, and from New Zealand in the south to Mongolia in the north;
o We will license to PhenoMed all necessary technology, know how, and processes required for PhenoMed to implement our disease management program throughout the region, which involves our President/Chief Medical Officer, David Moskowitz to train PhenoMed disease management program-licensed physicians in the proper use of our disease management program;
o We and PhenoMed agree to share equally (50-50) in the net profits obtained from the licensing and sale of the disease management services and related services sold anywhere throughout the Asia - Pacific region;
o Genotyping services provided by us to PhenoMed will be priced at $0.50 per genotype;
o Any of PhenoMed's third party genotyping contracts will abide by the contracted royalty payment and transfer terms we have made with any of our genotyping subcontractors;
o PhenoMed will grant us 15% of the common equity in PhenoMed.

Liquidity and Capital Resources
Cash at December 31, 2003 amounted to $11,469. Cash at April 16, 2004 amounted to $1,498,690.

During March 2004 the Company agreed to adjust the salary of its president to $183,907 per annum with $48,907 being paid in cash and the balance being paid in common shares of the Company with a 50% discount from the average closing price of the 30 day trading period prior to issuance.

During the period from January to April 5, 2004 the Company issued an aggregate of 1,869,231 shares of common stock for cash of $46,962 in addition to the shares described above.

The agreements with ADOT, Pierpoint and E&E are attached to the 10K as appendices.

[This message has been edited by 1BigTip (edited April 22, 2004).]

IP: Logged

1BigTip
Member
posted April 23, 2004 09:29     Click Here to See the Profile for 1BigTip     Edit/Delete Message   Reply w/Quote
GenoMed`s Treatment Showing 100% Response Rate Among Immunocompetent Patients; Nationwide Trial Gaining Momentum

April 23, 2004 08:45:00 (ET)


ST. LOUIS, Apr 23, 2004 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (Pink Sheets: GMED), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, said today that it will be limiting its treatment for West Nile virus encephalitis to immunocompetent patients only, where it has posted a 100% success rate.

Ten out of ten patients, including 4 over the age of 70, responded completely to GenoMed's treatment. The only failure since late August 2003 when the trial began was a young woman with chronic leukemia treated last September.

So far this April, 31 people have downloaded GenoMed's West Nile virus trial document. These include 4 physicians; 3 public health officers, including one from Manitoba, Canada and one from Arizona; 2 people from blood banks and 2 more from hospitals.

In addition, 6 patients with chronic residual disease after getting West Nile virus encephalitis last summer have signed up for GenoMed's trial. One patient with right leg paralysis who has been on GenoMed's treatment during the winter has recovered nearly complete function of his right leg.

GenoMed's patent-pending protocol uses blood-pressure drugs that are safe and already familiar to most physicians. They're carried in every drug store. The protocol, developed by Dr. David Moskowitz, the Company's Chairman, CEO and Chief Medical Officer, is based on the theory that brain inflammation and death result from an over-response by the patient's immune system to the West Nile virus. GenoMed's protocol gently suppresses the immune system at an early step in its activation. The results of Dr. Moskowitz's first eight patients will be published soon in a peer-reviewed medical journal.

If GenoMed's current 100% cure rate for patients who aren't immunosuppressed holds up, GenoMed hopes to prevent all deaths and cases of paralysis from West Nile virus encephalitis in the general population this season. Immunosuppressed patients include those with AIDS, those taking chemotherapy for cancer, and organ transplant recipients. GenoMed's treatment approach is already known not to work for this group, unfortunately. Two other biotechnology companies offer treatments which may benefit immunosuppressed patients.

For the general population, GenoMed recommends beginning its treatment protocol once a person develops fever and flu-like symptoms after a mosquito bite, and not waiting for encephalitis to develop.

GenoMed hopes to eliminate the threat of West Nile virus from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" button at http://www.genomedics.com .

Dr. Moskowitz is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz's research on viruses, including West Nile virus, avian influenza ("bird flu"), and SARS, are regarded as innovative approaches for otherwise incurable diseases.

About GenoMed

GenoMed is leading the medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. This summer the Company is conducting a nationwide free clinical trial for West Nile virus encephalitis which will be published before the 2005 West Nile virus season begins. If the Company's protocol continues to be successful, GenoMed will market it in 2005. GenoMed is currently marketing its protocol for delaying complications, such as kidney failure, of common diseases like high blood pressure and diabetes, which affect 80 million Americans, and emphysema, which affects another 3 million people in the U.S.

IP: Logged

1BigTip
Member
posted April 27, 2004 19:02     Click Here to See the Profile for 1BigTip     Edit/Delete Message   Reply w/Quote
As of April 26, 2004
Outstanding Shares = 161,452,849
Restricted Shares = 57,642,849
Float = 103.8 Million as of 3-4-04

IP: Logged

1BigTip
Member
posted May 13, 2004 15:45     Click Here to See the Profile for 1BigTip     Edit/Delete Message   Reply w/Quote
News out. Charts looking good.

2 non-profit groups which care for wild birds with West Nile virus encephalitis, including American bald eagles, will be using the Company's patent-pending treatment this season.


https://us.etrade.com/e/t/invest/Story?ID=STORYID%3Detrade_2004_05_13_eng-etrade_cbs2_market_watch_eng-etrade_cbs2_market_watch_1F0761DE-8A01-4754-9999-8BBA5661E2A8&provider=PRNews wire

IP: Logged

All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | Allstocks.com Home Page

© 1997 - 2004 Allstocks.com. All rights reserved.

Powered by Infopop www.infopop.com © 2000
Ultimate Bulletin Board 5.47a